Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
anti-CD33 CAR T / City of Hope, National Cancer Institute
NCT05672147: CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia	Recruiting	1	27	US	Anti-CD33 CAR T-cells, Anti-CD33 CAR T Cells, Anti-CD33 CAR-T Cells, CD33-CAR T Cells, Lymphodepletion Therapy, Lymphodepleting Therapy, Lymphodepletion	City of Hope Medical Center, National Cancer Institute (NCI)	Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia	09/28	09/28

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
anti-CD33 CAR T / City of Hope, National Cancer Institute
NCT05672147: CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia	Recruiting	1	27	US	Anti-CD33 CAR T-cells, Anti-CD33 CAR T Cells, Anti-CD33 CAR-T Cells, CD33-CAR T Cells, Lymphodepletion Therapy, Lymphodepleting Therapy, Lymphodepletion	City of Hope Medical Center, National Cancer Institute (NCI)	Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia	09/28	09/28